Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of WX390 monotherapy in PIK3CA-mutant gynecologic tumors
CTR20210445Phase 2Active
- Sponsor
- Cisen Pharmaceutical Co., Ltd.
- Start
- May 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of WXFL10030390 in ovarian cancer, endometrial cancer (EC), cervical squamous cell carcinoma (CSCC), sponsored by Cisen Pharmaceutical Co., Ltd.. Started May 2021; status: active.
02
Drugs
WXFL10030390
03
Conditions
ovarian cancerendometrial cancer (EC)cervical squamous cell carcinoma (CSCC)
Beyond the preview
Go deeper on CTR20210445.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20210445.